These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 18457229)

  • 1. The regulation of biotechnologies: four recommendations.
    Fox D
    Hastings Cent Rep; 2008; 38(2):1 p following 56. PubMed ID: 18457229
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulation of probiotic substances as ingredients in foods: premarket approval or "generally recognized as safe" notification.
    Mattia A; Merker R
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S115-8; discussion S144-51. PubMed ID: 18181714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The little agency that could (act with indifference to constitutional and statutory strictures).
    Noah L
    Cornell Law Rev; 2008 Jul; 93(5):901-26. PubMed ID: 18618963
    [No Abstract]   [Full Text] [Related]  

  • 4. Dirty dancing--the FDA stumbles with the Chevron two-step: a response to professor Noah.
    Lawson G
    Cornell Law Rev; 2008 Jul; 93(5):927-38. PubMed ID: 18618964
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA regulatory compliance reconsidered.
    Tobias C
    Cornell Law Rev; 2008 Jul; 93(5):1003-38. PubMed ID: 18618969
    [No Abstract]   [Full Text] [Related]  

  • 6. The ability of current biologics law to accommodate emerging technologies.
    Carter MJ
    Food Drug Law J; 1996; 51(3):375-80. PubMed ID: 11797714
    [No Abstract]   [Full Text] [Related]  

  • 7. American roulette--contaminated dietary supplements.
    Cohen PA
    N Engl J Med; 2009 Oct; 361(16):1523-5. PubMed ID: 19812394
    [No Abstract]   [Full Text] [Related]  

  • 8. US animal biotech regulations "may not be adequate".
    Fox JL
    Nat Biotechnol; 2002 Oct; 20(10):959. PubMed ID: 12355099
    [No Abstract]   [Full Text] [Related]  

  • 9. Lessons learned from good manufacturing practice noncompliance.
    Peskoe MP
    Food Drug Law J; 1995; 50(1):65-70. PubMed ID: 10342986
    [No Abstract]   [Full Text] [Related]  

  • 10. Anticipating new consumer protection challenges in the food and drug marketplace.
    Parnes LB
    Food Drug Law J; 2008; 63(2):593-9. PubMed ID: 18561480
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulation of cosmetics that are also drugs.
    Greff JA
    Food Drug Law J; 1996; 51(2):243-72. PubMed ID: 11820201
    [No Abstract]   [Full Text] [Related]  

  • 12. Reforming the food safety system: what if consolidation isn't enough?
    Harv Law Rev; 2007 Mar; 120(5):1345-66. PubMed ID: 17410681
    [No Abstract]   [Full Text] [Related]  

  • 13. The importance and challenges of "mutual recognition".
    Merrill RA
    Seton Hall Law Rev; 1998; 29(2):736-55. PubMed ID: 10569829
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotechnology and the food label: a legal perspective.
    Degnan FH
    Food Drug Law J; 2000; 55(3):301-10. PubMed ID: 11824462
    [No Abstract]   [Full Text] [Related]  

  • 15. Food security would be compromised by combining the Food and Drug Administration and the U.S. Department of Agriculture into a single food agency.
    Pape SM; Rubin PD; Kim H
    Food Drug Law J; 2004; 59(3):405-16. PubMed ID: 15586990
    [No Abstract]   [Full Text] [Related]  

  • 16. Food safety inspections: a call for rational reorganization.
    DeWaal CS
    Food Drug Law J; 1999; 54(3):453-8. PubMed ID: 11797708
    [No Abstract]   [Full Text] [Related]  

  • 17. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 18. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 19. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
    Dudzinski DM
    Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA law enforcement: critical to product safety.
    Rados C
    FDA Consum; 2006; 40(1):21-7. PubMed ID: 16528823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.